Central nervous system relapse after allogeneic HCT in FLT3-mutated AML
Annals of Hematology · 2024
DOI: 10.1007/s00277-024-06106-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, 2024. Verfasst von Khouloud Kouidri und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine 2, Hematology/Oncology, Goethe University Frankfurt, University Hospital, Frankfurt, Germany. Kouidri@med.uni-frankfurt.de. Hauptthemen laut MEDLINE: fms-Like Tyrosine Kinase 3, Leukemia, Myeloid, Acute, Hematopoietic Stem Cell Transplantation, Mutation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Johann Wolfgang Goethe-Universität, Frankfurt am Main.
Abstract (Originalsprache)
Central nervous system (CNS) relapse in acute myeloid leukemia (AML) is rare, but prognostically extremely unfavorable and associated with very high mortality rates. Aim of our single-center study was to define risk factors for CNS relapse in patients with FLT3 -mutated AML after allogeneic hematopoietic cell transplantation (HCT) and to determine the impact of pre-emptive or salvage therapy with FLT3-inhibitors (FLT3i) on occurrence of CNS relapse and overall prognosis. We analyzed 39 FLT3 -mutated AML patients who were treated with intensive induction therapy and consecutively underwent HCT at our institution. We observed that the remission status before HCT was strongly associated with relapse probability. Notably, FLT3 -mutated AML showed a high propensity for CNS relapse with a cumulative incidence of 50% (95% confidence interval [CI], 16–77) at 2 years in non-responders pre-HCT compared to 0% in responders (cause-specific hazard ratio, 24.5, 95% CI, 2.9-206.2; p = 0.003). This was not abrogated by pre-emptive or salvage therapy with FLT3i in first relapse. Targeted therapies prior to transplant, use of intrathecal chemoprophylaxis or closer monitoring may be considered in patients with FLT3-mutated AML with active disease prior to HCT in order to prevent CNS relapse.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine 2, Hematology/Oncology, Goethe University Frankfurt, University Hospital, Frankfurt, Germany. Kouidri@med.uni-frankfurt.de.
- Department of Medicine 2, Hematology/Oncology, Goethe University Frankfurt, University Hospital, Frankfurt, Germany.
- Dana Farber Cancer Institute, Boston, MA, United States of America.
- Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Förderung
- Johann Wolfgang Goethe-Universität, Frankfurt am Main
Zitieren
APA
Kouidri, K., Acker, F., Toenges, R., Pfaff, S., Lindner, S., Riemann, J., Werth, M., Ajib, S., Lang, F., Steffen, B., Oellerich, T., Serve, H., Cremer, A., & Bug, G. (2024). Central nervous system relapse after allogeneic HCT in FLT3-mutated AML. Annals of Hematology. https://doi.org/10.1007/s00277-024-06106-y
Vancouver
Kouidri K, Acker F, Toenges R, Pfaff S, Lindner S, Riemann J, et al. Central nervous system relapse after allogeneic HCT in FLT3-mutated AML. Annals of Hematology. 2024. doi:10.1007/s00277-024-06106-y
BibTeX
@article{Kouidri2024,
author = {Kouidri, Khouloud and Acker, Fabian and Toenges, Rosa and Pfaff, Saskia and Lindner, Sarah and Riemann, Julia and Werth, Marek and Ajib, Salem and Lang, Fabian and Steffen, Björn and Oellerich, Thomas and Serve, Hubert and Cremer, Anjali and Bug, Gesine},
title = {Central nervous system relapse after allogeneic HCT in FLT3-mutated AML},
journal = {Annals of Hematology},
year = {2024},
doi = {10.1007/s00277-024-06106-y}
}
EUVIMED